Evidence map›Paper›PMID 35932324›Full record

ArticleAnnals of hematology2022

Maternal and fetal outcomes of pregnancy occurring after a diagnosis of immune-mediated thrombotic thrombocytopenic purpura.

Jenna Brown, Bindu Potugari, Marshall A Mazepa, Ruhail Kohli, Alison R Moliterno, Robert A Brodsky, Jason A Vaught, Richard Burwick, Shruti Chaturvedi

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Challenges and opportunities in the long-term management of immune-mediated TTP.Hematology. American Society of Hematology. Education Program · 2025
    Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Jenna BrownJohns Hopkins University, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-7789-4175
Bindu PotugariDivision of Hematology and Oncology, Saint Joseph Mercy Ann Arbor Hospital, Ann Arbor, MI, USA.
Marshall A MazepaDivision Hematology and Oncology, University of Minnesota School of Medicine, Minneapolis, MN, USA.
Ruhail KohliDivision of Gastroenterology and Hepatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Alison R MoliternoDivision of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, 720 Ross Research Building Rutland Avenue, Room 1025, Baltimore, MD, 21205, USA.
Robert A BrodskyDivision of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, 720 Ross Research Building Rutland Avenue, Room 1025, Baltimore, MD, 21205, USA.
Jason A VaughtDepartment of Obstetrics and Gynecology, Johns Hopkins University, Baltimore, MD, USA.
Richard BurwickDepartment of Obstetrics and Gynecology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Shruti ChaturvediDivision of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, 720 Ross Research Building Rutland Avenue, Room 1025, Baltimore, MD, 21205, USA. schatur3@jhmi.edu.
Johns Hopkins University · USCedars-Sinai Medical Center · USTrinity Health Ann Arbor Hospital · USUniversity of Minnesota · US

Funding

ADAMTS13 and Late Neurologic Morbidity after Thrombotic Thrombocytopenic PurpuraK99HL150594 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI CHATURVEDI, SHRUTI · 2020 to 2023
$907k
NHLBI NIH HHS K99 HL150594
6 · The paper itself

Abstract

Pregnancy is a well-established trigger for a first episode or relapse of immune thrombotic thrombocytopenic purpura (iTTP). Other outcomes of subsequent pregnancy after a diagnosis of iTTP are less well described. We conducted this retrospective cohort study to evaluate maternal and fetal outcomes of pregnancy in women with prior iTTP from the Johns Hopkins Thrombotic Microangiopathy Cohort. Of 168 women in the cohort, 102 were of reproductive age at diagnosis. Fourteen pregnancies (in 9 women) that occurred after the initial iTTP episode were included in the analysis. iTTP relapse occurred in 9 (64%) pregnancies. Out of the 9 instances of relapse, 5 relapses occurred in 2 women. Seven pregnancies (50%) ended in fetal death or miscarriage in the setting of iTTP relapse and three were electively terminated due to fear of relapse. Four pregnancies (50% of the 8 that progressed beyond 20 weeks) were complicated by preeclampsia or HELLP syndrome, which is over ten-fold higher than that of the general population. No maternal deaths occurred. Only 4 pregnancies resulted in live births, of which, 2 were pre-term. Pregnancy in women with prior iTTP is associated with a substantial risk of iTTP relapse and fetal loss. Preeclampsia and HELLP syndrome is also more common than that in the general population. ADAMTS13 monitoring and preemptive therapy may improve pregnancy outcomes, which needs to be evaluated prospectively.

Indexed as

HELLP SyndromePre-EclampsiaPurpura, Thrombocytopenic, IdiopathicPurpura, Thrombotic ThrombocytopenicADAMTS13 ProteinFemaleHumansPregnancyRecurrenceRetrospective StudiesADAMTS13 ProteinADAMTS13PreeclampsiaPregnancyThrombotic thrombocytopenic purpura

Identifiers

PMID35932324
PMCPMC11060143
OpenAlexW4290005022

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.